Clinical Research

Cardiac manifestations and diagnostic imaging in pediatric inflammatory multisystem syndrome temporally associated with COVID-19: a systematic review
Gilbert Sterling Octavius,1 Ricardo Tan,1 Teodorus Alfons Pratama,1 Charista Lydia Budiputri,1 Fellisa Meliani,1 Rivaldo Steven Heriyanto,1 Rusli Muljadi,2 Andry Juliansen3

ABSTRACT

BACKGROUND Several studies have reported pediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) cases with their cardiac manifestations, but only few studies synthesize the cardiovascular characteristics in children with PIMS-TS. However, detecting cardiac abnormalities is crucial in improving patients’ outcomes and reducing mortality. This review aimed to summarize the overall symptoms, laboratory, and workup findings in PIMS-TS patients, focusing on cardiovascular manifestations.

METHODS We searched 4 medical databases (PubMed, Science Direct, Medline, and Scielo) and 4 preprint databases (Medrxiv, Research Square, SSRN, and Biorxiv). The literature search was done on November 8, 2021. All case reports, case series, cross-sectional studies, cohort studies, and possible clinical trials published from December 2020 onward that studied PIMS-TS on cardiac manifestation (aged 0–18 years) were included. Studies on multisystem inflammatory syndrome in children, animal studies, and studies without full-text availability were excluded. This review was registered in PROSPERO (CRD42021194468).

RESULTS 59 studies were included with a total of 698 patients. The most common cardiovascular findings were the presence of cardiogenic shock (37%) and hypotension (8.5%). Almost all laboratory values were deranged. Cardiac computed tomography scan mostly showed normal results (56%), followed by cardiomegaly with pericardial effusion (14%). Electrocardiography showed normal findings (46%), ST-segment abnormalities (32%), and abnormal T wave (12%). Echocardiography findings showed left ventricle dysfunction (40.6%), which can be considered most significant, followed by pericardial effusion together with pericarditis (11.4%) and tricuspid regurgitation (6.9%).

CONCLUSIONS This review found various cardiac abnormalities that may develop during PIMS-TS. Due to these findings, we should be more vigilant and not underestimate the consequences in pediatric COVID-19 patients.

KEYWORDS cardiovascular, COVID-19, echocardiography, pediatrics, PIMS-TS

Copyright @ 2022 Authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are properly cited. For commercial use of this work, please see our terms at https://mji.ui.ac.id/journal/index.php/mji/copyright.
inflammatory syndrome in children (MIS-C). These two terms differ in which the latter requires COVID-19 evidence or at least close contact with COVID-19 patients.

PIMS-TS is a rare syndrome that shares standard features with other pediatric inflammatory conditions; this includes the involvement of other organ system dysfunctions such as gastrointestinal, respiratory, nervous, and cardiovascular systems. The dysfunction of these organs could still linger, even though PIMS-TS has been treated. The cardiovascular system is one of the most critically affected organ systems, which can cause long-term symptoms such as chronic fatigue, dyspnea, and chest pain. It would indeed affect the quality of life of children that were affected by PIMS-TS.

Several studies have reported PIMS-TS cases with their cardiac manifestations, but the results were varied. Acute cardiac decompensation due to hyperinflammation in patients with MIS-C results in longer hospital stay and higher mortality. Hence, it is crucial to detect cardiovascular abnormalities to improve patients' outcomes. To the best of our knowledge, only few studies have synthesized the cardiology symptoms, laboratory findings, and echocardiography characteristics in children with PIMS-TS. Furthermore, the long-term cardiac sequelae in PIMS-TS patients are still unknown. Thus, this review aimed to summarize the overall symptoms, laboratory, and diagnostic workup findings in PIMS-TS patients, focusing on the cardiovascular manifestations.

**METHODS**

This systematic review followed the Preferred Reporting Items for Systematic Review and Meta-Analyses 2020 statement. The protocol has been registered into the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42021194468).

The literature search was limited to studies published from December 2020 to October 2021, without language restrictions. All case reports, case series, cross-sectional studies, cohort studies, and possible clinical trials that studied the effects of PIMS-TS in pediatric cardiology patients with COVID-19 (aged 0–18 years) were included in this review. Exclusion criteria comprised MIS-C, animal studies, and studies without full-text references. Abstracts, letters to the editor, and reviews were screened for references to ensure literature saturation before they were excluded.

The literature search was done on November 8, 2021. The authors utilized four distinct databases, including PubMed, Science Direct, Medline, and Scielo and four different preprint databases, including Medrxiv, Research Square, SSRN, and Biorxiv. Differences in databases may be due to different types of studies, population variations, and case severity. PubMed indexed “ahead of print” articles. Therefore, the latest articles sometimes appear in PubMed but not in Medline. The keywords included “pediatric” AND (“PIMS-TS” OR “pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2”) AND (“cardiac” OR “cardiology” OR “echocardiography” OR “myocarditis” OR “heart failure”). Data were compiled in a standardized format, including study citations, demographic characteristics of the included participants (age, sex, and comorbidities), severe acute respiratory syndrome coronavirus 2 test results, signs and symptoms, laboratory results, treatments, length of stay, and outcomes. Cardiac-specific examinations such as computed tomography (CT) scan, echocardiography, and electrocardiogram (ECG) were also obtained from each study. If some data were missing, an email would be sent to the corresponding author.

Four independent reviewers (GSO, FM, RSH, and CLB) conducted the initial search and quality assessment of each study. The Joanna Briggs Institute's (JBI) essential evaluation checklist for case reports was used to measure the general consistency of case series and case reports. Meanwhile, the Newcastle-Ottawa quality assessment scale (NOS) was assessed for cross-sectional and longitudinal studies. Any discrepancies between JBI and NOS assessments were discussed until a conclusion was reached. Any unresolved disagreements would be consulted with two expert reviewers (RM and AJ). The included case reports should fulfill most of the JBI criteria and score ≥7 in the NOS score.

Pooled descriptive tests were used to combine all data in this review. Data presented in median and range (or interquartile range) were converted into mean and standard deviation (SD). All the means and
SDs were then combined into a single value using the Cochrane method.²²

RESULTS

There are 59 studies included in this review, with the selection process is shown in Figure 1. All individual studies achieved good results in JBI and NOS scores, and each study is listed in Table 1. A total of 698 patients were included, with a mean (SD) age of 9.2 (4.1) years and male predominance (58.0%). The demographic characteristics of the patients are shown in Table 2. Most patients had positive polymerase chain reaction tests.

Nutritional problems such as underweight or obesity were the most common comorbidities, followed by respiratory problems and neurologic disorders (Table 2). Many patients experienced a shock. The mean (SD) length of hospital stay was 9.8 (11.3) days. Intravenous immunoglobulin was commonly used for PIMS-TS. Of 600 patients with available data on mortality, 3.33% died.

The mean (SD) of systolic and diastolic blood pressure were 81 (14) and 46 (12), respectively. Almost all laboratory values were deranged in PIMS-TS patients (Table 2). Notably, there was an increase in white blood cells count, neutrophil, C-reactive protein (CRP), ferritin, procalcitonin, creatinine kinase, creatinine, alanine transaminase, aspartate aminotransferase, D-dimer, fibrinogen, and erythrocyte sedimentation rate, and almost all cardiac markers were also elevated. Meanwhile, hemoglobin and lymphocyte values were decreased (Table 2).

The reference range in this table followed the normal values for 9-years-old children (mean age of this study) that were obtained from the Nelson Textbook of Pediatrics²³ and Mosby's Manual of Diagnostic and Laboratory Tests.²⁴ High sensitivity troponin T values were taken from Calò Carducci et al.²⁵

The most common cardiac CT scan result was normal (56%), followed by cardiomegaly with pericardial effusion (14%). Among 121 patients, the ECG evaluation results were mostly normal (46%). ST abnormalities (32%) and abnormal T wave
| First author, year | Study design       | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n)                                                                 | Oxygen support (n)                                                                 | Treatment                                                                 | Length of stay (days) | Death (n) |
|--------------------|-------------------|--------------------------|----------------------------|---------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------|-----------|
| de Farias, 2020    | Prospective       | 11 (81)                  | 4 (0.6–11)                 | NA            | Extreme prematurity, chronic neonatal lung disease, and ischemic hypoxic        | Invasive mechanical ventilation (3) and non-invasive mechanical ventilation (4) | Corticosteroid, IVIG single-dose 2 g/kg, ASA, and enoxaparin dose 3 mg/kg | Median (range) = 17 | 2         |
|                    | observational     |                          |                            |               | encephalopathy (1); chronic post-traumatic encephalopathy and chronic           |                                                                                   |                                                                         | 12–180                |           |
|                    |                   |                          |                            |               | respiratory failure did not depend on oxygen, tracheostomy (1); overweight     |                                                                                   |                                                                         |                       |           |
|                    |                   |                          |                            |               | (3); none (3); mild asthma (2); and obesity (3)                                |                                                                                   |                                                                         |                       |           |
| Penner, 2021       | Retrospective     | 46 (65)                  | 10.2 (IQR 8.8–13.3)        | White (9),    | Autism (4), sickle cell disease (2), asthma (1), type 1 diabetes (1), spina   | Mechanical ventilation (16)                                                      | IV fluid bolus, inotrope/vasopressor, hydrocortisone, methylprednisolone, and broad-spectrum antibiotic | Median (IQR) = 11    | 0         |
|                    | cohort             |                          |                            | South Asian (11), African-Caribbean (16), and others (10) | bifida (1), autism, and sickle cell disease (1)                                 |                                                                                   |                                                                         | 8–16                  |           |
| Ramcharan, 2020    | Retrospective     | 15 (73.3)                | 8.8 (IQR 6.4–11.2)         | African         | Mechanical ventilation (4), HFNC (4), and NA (7)                               | IV fluid bolus, inotrope/vasopressor, hydrocortisone, methylprednisolone, and broad-spectrum antibiotic | NA                                                                 |                       | 0         |
|                    | observational      |                          |                            | Afro-Caribbean (6), South Asian (6), Mixed (2), and other (1) |                                                                                   |                                                                                   |                                                                         |                       |           |
| Jhaveri, 2020      | Retrospective     | 15 (60)                  | 11.5 (3–20)                | NA            | NA                                                                                | NA                                                                               | IVIG, corticosteroid, tocilizumab, anakinra, therapeutic anticoagulant, remdesivir, plasma therapy, aspirin during admission, and vasopressor | NA                    | 1         |
|                    | observational      |                          |                            |               |                                                                                   |                                                                                  |                                                                         |                       |           |
| Kaushik, 2020      | Retrospective     | 33 (61)                  | 10 (6–13)                  | Hispanic (15), | Overweight (4), obesity (2), asthma (5), allergic rhinitis/eczema (3), cardiac | Non-invasive mechanical ventilation (12), invasive mechanical ventilation (5),   | IVIG, corticosteroid, tocilizumab, remdesivir, anakinra, convalescent plasma, norepinephrine, dopamine, epinephrine, dobutamine, vasopressor, milrinone, aspirin, diuretics, anticoagulant prophylaxis, anticoagulation therapeutic, antibiotic <48 hours, and antibiotic >48 hours | Median (IQR) = 7.8    | 1         |
|                    | observational      |                          |                            | Black (13), White (3), Asian (1), and other (1) | comorbidity (2), hematologic comorbidity (2), and others (3)                    | ECMO (1), and intra-aortic balloon pump (1)                                      |                                                                         | 6.0–10.1              |           |

Table continued on next page
| First author, year | Study design | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n) | Oxygen support (n) | Treatment | Length of stay (days) | Death (n) |
|-------------------|--------------|--------------------------|-----------------------------|---------------|-------------------|-------------------|-----------|----------------------|-----------|
| Grimaud, 2020     | Retrospective observational | 20 (50) | 10 (2.9–15) | NA | NA | Non-invasive ventilation (11), invasive ventilation (8), and high-flow nasal oxygen (1) | IVIG, inotropic/vasoactive (epinephrine, milrinone, dopamine, and norepinephrine), corticosteroids, IL-1 receptor antagonist, and IL-6 receptor antagonist | NA | 0 |
| Lee, 2020         | Retrospective | 28 (57) | 9 (1 month–17 years) | Hispanic (12), White (10), and Black (6) | None | Non-invasive ventilation (7) and nasal cannula (4) | Vasopressors, IVIG, anakinra, remdesivir, antibiotics, and anticoagulants | NA | 0 |
| Biko, 2020        | Retrospective | 10 (100) | 9 (5–15) | NA | Type 2 neuronal ceroid lipofuscinosis (1), prematurity (1), and asthma (1) | Ventilatory support (9) | IVIG, steroids, and plasma antibodies | Range 3–76, remained hospitalized = 1 | 0 |
| Blumfield, 2020   | Retrospective | 16 (37.5) | 9.2 (SD 4.9), range = 20 months–20 years | NA | Overweight/obesity (4), asthma (1), primary immunodeficiency GATA3 deficiency (1), and prematurity (1) | Intubation and mechanical ventilation (1) | NA | NA |
| Cheung, 2020      | Retrospective | 17 (47) | 8 (1.8–16) | Ashkenazi Jewish (6), White non-Hispanic (2), White Hispanic (4), Black (4), and Asian (1) | Asthma (3) | NA | Corticosteroid, IVIG, tocilizumab, prophylactic enoxaparin, and aspirin | Median (range) = 7.1 (3–18) | NA |
| Matsubara, 2020   | Retrospective | 28 (50) | 11.4 (IQR 8.0–13.7) | African American (13), Caucasian (7), Hispanic (4), Asian (1), and NA (3) | Obesity (3), overweight (9), and NA (16) | Invasive ventilation (7), continuous airway pressure (2), BiPAP (5), and NA (14) | Aspirin, IVIG, vasopressor, corticosteroid, and anticoagulants | NA | NA |

Table continued on next page
Table 1. (continued)

| First author, year | Study design  | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n) | Oxygen support (n) | Treatment                                                                 | Length of stay (days) | Death (n) |
|--------------------|---------------|---------------------------|----------------------------|---------------|------------------|-------------------|--------------------------------------------------------------------------|-----------------------|-----------|
| Mamishi, 52 2020   | Retrospective | 45 (53)                   | 7 (10 month–17 years)     | NA            | Acute lymphocytic leukemia, chronic kidney disease, underlying seizure disorder, cerebral palsy, cardiovascular disease, and Budd-Chiari syndrome in 6 patients | NA                 | IVIG and steroid                                                        | NA                    | 5         |
| Bartoszek, 53 2021 | Retrospective | 19 (73.7)                 | 10 (IQR 10–15)            | NA            | NA               | NA                | IVIG in 19 patients and steroid in 12 patients                           | Median (IQR) = 11 (7–14.5) | 0         |
| Pouletty, 54 2020  | Retrospective | 16 (50)                   | 10 (IQR 4.7–12.5)         | NA            | Overweight (4), asthma (2), and NA (10) | Non-invasive ventilation (3) and NA (13) | IVIG, single infusion, double infusion, steroids, anti-IL-1 treatment, anti-IL-6 treatment, HCO, and aspirin | NA                    | 0         |
| Riolano-Cruz, 55 2020 | Retrospective | 12 (66.7)                 | 11.5 (3–17)               | Hispanic or Latino (8), non-Hispanic African American (2), non-Hispanic White (2), and NA (1) | Asthma (3), hypothyroidism and NAFLD (1), and NA (8) | Mechanical ventilation (2), non-invasive ventilation (3), SVIA (1), and none (6) | Vancomycin, cefepime, metronidazole, IVIG, tocilizumab, enoxaparin, clindamycin, norepinephrine, vasopressin, amiodarone, lidocaine, meropenem, anakinra, remdesivir, mirinone, cefazolin, ceftriaxone, dopamine, linezolid, and metronidazole | Median (range) = 7.5 (4–13) | 1         |
| Belhadjer, 57 2020  | Retrospective | 35 (51.4)                 | 10 (1–16)                 | NA            | Asthma (3), lupus (1), overweight (6), and NA (25) | Invasive respiratory support (22) and non-invasive (11) | Inotropic support, IVIG, IV corticosteroids, IL-1 receptor antagonist, and anticoagulant with heparin | 5                     | 0         |
| Davies, 56 2020    | Observational | 78 (67)                   | 11 (1–17)                 | NA            | None (61), usually expected to require primary care (15), and usually expected to require hospital care (2) | None (12), oxygen only (12), HFNC (13), non-invasive ventilation (5), invasive mechanical ventilation (36), and ECMO (3) | Antibiotics, steroids, IVIG, immunomodulation with biologic agents, anakinra, infliximab, tocilizumab, rituximab, aspirin or other antiplatelet therapy, anticoagulation prophylactic, anticoagulation therapeutic, and antiviral therapy (remdesivir) | Median (IQR) = 5 (3–6.5) | 2         |
| First author, year | Study design | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n) | Oxygen support (n) | Treatment | Length of stay (days) | Death (n) |
|-------------------|-------------|--------------------------|-----------------------------|---------------|-------------------|-------------------|-----------|----------------------|----------|
| Torres, 2020      | Observational | 27 (51.8) | 6 (0–14) | NA | Overweight/obesity (4), asthma (1), GATA3 deficiency (1), prematurity gestational age of 33 weeks (1), and none (20) | Oxygen (13), invasive mechanical ventilation (12), and NA (2) | Antibiotic treatment, acetylsalicylic acid, anticoagulant therapy, IVIG, and systemic corticosteroid | Median (IQR) = 9 (6–13) | 0 |
| Darren, 2021      | Observational | 18 (55) | 8.9 (0.3–14.6) | Black, Asian, and minority ethnic 89%, 16/18 | NA | HFNC (5), supplemental oxygen (3), invasive ventilation (3), and none (8) | IVIG, methylprednisolone, tocilizumab, and infliximab | NA | 0 |
| Ng, 2020          | Case series   | 3 (67) | 16 (13–17) | Asian Indian (1) and Afro-Caribbean (2) | NA | Nasal cannula (2) and mechanical ventilation (1) | Vasopressor, IVIG, steroid, aspirin, and antibiotic | NA | 0 |
| Paolino, 2021     | Case series   | 3 (67) | 8 (6–9) | African American (2) and NA (1) | NA | NA | NA | NA | 0 |
| Prieto, 2020      | Case series   | 5 (60) | 7 (IQR 5–12) | Caucasian (2), Hispanic (1), Arab (1), and Sub-saharan African (1) | Psoriasis (1) and post-operative tonsillectomy (1) | Nasal cannula (3) and BiPAP (1) | Dopamine, norepinephrine, ceftriaxone, IVIG (2 g/kg), steroids (2 mg/kg), HCQ, and azithromycin | NA | 0 |
| Harwood, 2020     | Case series   | 2 (50) | 8.5 (3–14) | NA | None | Mechanical ventilation (1) and nasal cannula (1) | Inotropic support, IVIG, steroid, aspirin, and antibiotics | Median (range) = 8 (4–11) | 0 |
| Lishman, 2020     | Case series   | 4 (50) | 8 | NA | Perforated appendicitis (2), appendicitis (1), and NA (3) | Mechanical ventilation (1) and nasal cannula (1) | Inotropic support, IVIG, steroid, aspirin, and antibiotics | Median (range) = 12 (10–14) | 0 |
| Calò Carducci, 2020 | Case series | 2 (100) | 13.5 (13–14) | Caucasian (2), Hispanic (1), Arab (1), and Sub-saharan African (1) | None | NA | Methylprednisolone, anakinra, lopinavir, and LMWH | Median (range) = 12 (10–14) | 0 |

Table continued on next page
| First author, year | Study design   | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n) | Oxygen support (n) | Treatment                                                          | Length of stay (days) | Death (n) |
|--------------------|----------------|---------------------------|-----------------------------|---------------|-------------------|-------------------|---------------------------------------------|------------------------|-----------|
| Dallan, 2020       | Case series    | 2 (100)                   | 10                          | Mixed-race (Asian and White) (1) and Black (1) | Obesity (2)   | Non-invasive mechanical ventilation (1) and invasive mechanical ventilation (1) | HCQ, azithromycin, and anakinra | 12, remained hospitalized = 1 | 0         |
| Wolfle, 2020       | Case series    | 5 (40)                    | 6 (0.17–14)                 | NA            | NA                | Non-invasive mechanical ventilation (1) | IVIG, epinephrine, antibiotic, prophylactic LMWH, steroid, tocilizumab, PDE3 inhibitor, and HCQ | Median (range) = 7.2 (5–10) | NA        |
| Rogo, 2020         | Case series    | 4 (67)                    | 5 (3–17)                    | NA            | NA                | ECMO (1)          | Vasopressor, IVIG, and tocilizumab       | NA                     | 1         |
| Shahbaznejad, 2020 | Case series    | 10 (60)                   | 5.75 (1.1–12)              | Iranian (10)  | Chronic renal failure (1) | Intubation (1), oxygen hood (1), none (3), and NA (4) | Oseltamivir, meropenem, vancomycin, HCQ, IVIG, packed red cells, ceftriaxone, zinc gluconate, albumin, vasoactive drugs, clindamycin, cefotaxime, vitamin D, and diclofenac | Median (range) = 11.19.5 (3–2417) | 1         |
| Nathan, 2020       | Case series    | 2 (0)                     | 8 (5–11)                   | NA            | Overweight (2)    | Mechanical ventilation (2) | Appendicectomy, post-operative diagnosis of myopericarditis, inotropic support, and antibiotic | Median (range) = 16.5 (12–21) | 0         |
| Wehl, 2021         | Case series    | 3 (33.3)                  | 14 (7–17)                  | Turkish-German (1) and German (2) | None           | NA            | Antibiotics, IVIG, and acetylsalicylic acid | Median (range) = 9 (7–13) | 0         |
| Mehta, 2021        | Case series    | 21 (50)                   | (6–7.5)                    | NA            | NA                | None              | IVIG and methylprednisolone               | Median (range) = 8.5 (5–12) | 0         |
| Mukund, 2020       | Case series    | 3 (100)                   | 7 (6.5–12)                 | NA            | AKI stage 2 (1)   | Non-invasive ventilator (1) and low-flow oxygen (2) | Adrenaline, IVIG, methylprednisolone, and azithromycin | Median (range) = 20 (16–32) | 0         |

Table continued on next page
| First author, year | Study design | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n) | Oxygen support (n) | Treatment | Length of stay (days) | Death (n) |
|-------------------|-------------|--------------------------|----------------------------|--------------|-------------------|-------------------|------------|----------------------|-----------|
| Capone, 2020      | Case series | 33 (61)                  | 8.6 (2.2–17)               | Hispanic (9) and non-Hispanic (23) | Obesity (13), asthma or reactive airway disease (5), renal tubular acidosis (1), and hemodynamically insignificant ventricular septal defect (1) | Mechanical ventilation (6) and required oxygen or PPV (17) | IVIG, methylprednisolone, aspirin, anakinra, tocilizumab, infliximab, and enoxaparin | Median (IQR) = 4 (4–8) | 0         |
| Whittaker, 2020   | Case series | 58 (43)                  | 9 (5.7–14)                 | Black (22), Asian (18), White (12), and others (6) | Asthma (3), neurological disability (1), epilepsy (1), sickle cell trait (1), and alopecia (1) | Mechanical ventilation (23), intubation (25), and ECMO (3) | IVIG, corticosteroids, anakinra, and infliximab | NA | 1         |
| Blumfield, 2020   | Case series | 19 (53)                  | 8 (2 months–18 years)     | NA           | Severe neurologic impairment (5), morbid obesity (3), congenital heart disease (1), metastatic cancer (1), asthma (1), hypertension (1), sickle cell disease (1), prior thromboembolic events (1), and fragile X syndrome (1) | Intubation (8), HFNC (1), and BiPAP (1) | NA | NA         |
| Waltuch, 2020     | Case series | 3 (100)                  | 5 (5–13)                  | NA           | Hypothyroid (1) and asthma (1) | BiPAP and intubation (1) | Meropenem, linezolid, enoxaparin, IVIG, tocilizumab, anakinra, cefepime, clindamycin, ceftriaxone, and dopamine | NA | NA        |
| Chiotos, 2020     | Case series | 6 (17)                   | 7.5 (5–14)                | Black (2), White (2), and NA (2) | None | Mechanical ventilation (3) and invasive mechanical ventilation (2) | Vasoactive support, IVIG, methylprednisolone 2 mg/kg/day, antibiotic, tocilizumab, and corticosteroid | Median (range) = 11 (8–17); NA = 5 | 0         |
| Patel, 2021       | Case report | 1 (100)                  | 16                         | NA           | None | NA | Acyclovir, ceftriaxone, paracetamol, IVIG, and aspirin | NA | 0         |
| Gupta, 2020       | Case report | 1 (100)                  | 1.9                        | Asian (2)    | None | Nasal cannula | Dopamine, norepinephrine, antibiotics, and IVIG (2 g/kg) methylprednisolone | 4 | 0         |
| First author, year | Study design | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n) | Oxygen support (n) | Treatment | Length of stay (days) | Death (n) |
|-------------------|-------------|--------------------------|-----------------------------|---------------|-------------------|-------------------|-----------|----------------------|-----------|
| Rauf, 2020        | Case report | 1 (100)                  | 5                           | Asian         | None              | Nasal cannula     | Adrenaline, IV ceftriaxone, IVIG (2 g/kg), methylprednisolone pulse (30 mg/kg/day), diuretics, and enalapril | 6         | 0                    |
| Gupta, 2020       | Case report | 1 (0)                    | 7                           | Indian        | None              | NA                | Meropenem, IV (2 g/kg), aspirin (3 mg/kg), and methylprednisolone (15 mg/kg/day) | NA        | 0                    |
| Balasubramanian, 2020 | Case report | 1 (100)                  | 8                           | Indian        | None              | Nasal cannula     | Ceftriaxone, tocilizumab (8 mg/kg IV over 2 hours), IVIG (2 g/kg), and aspirin (75 mg 1x/day) | 14        | 0                    |
| Schneider, 2020   | Case report | 1 (100)                  | 9                           | NA            | None              | NA                | Prednisolone       | NA        | 0                    |
| Orlanski-Meyer, 2020 | Case report | 1 (0)                    | 6.5 (0–12)                  | Inflammatory bowel syndrome | NA                | Pulse methylprednisolone therapy (30 mg/kg/day), prednisolone (2 mg/kg/day), anakinra (3.5 mg/kg/day), and IVIG (2 g/kg) | NA        | 0                    |
| Masih, 2020       | Case report | 1 (100)                  | 9                           | Caucasian (2) and Hispanic (1) | Asthma            | Face mask         | Ceftriaxone, clarithromycin, IVIG, and IV methylprednisolone | 7         | 0                    |
| Meredith, 2020    | Case report | 1 (0)                    | 10                          | Polynesian/Caucasian | Ulcerative colitis | NA                | IVIG (2 g), high-dose IV methylprednisolone (1 g), aspirin (10 mg/kg), proton-pump inhibitor, adjuvant thromboprophylaxis, IV piperillin/tazobactam, and IV meropenem | 28        | 0                    |
| Ghatasheh, 2021   | Case report | 1 (100)                  | 0.75                        | Asian         | None              | NA                | IVIG, anticoagulation, and antiplatelet | 21        | 0                    |
| Dasgupta, 2020    | Case report | 1 (0)                    | 8                           | NA            | None              | None              | Vasopressor, IVIG, corticosteroid, aspirin, and antibiotic | 11        | 0                    |
| Klocperk, 2020    | Case report | 1 (0)                    | 8                           | NA            | None              | Nasal cannula (1) | IV methylprednisolone 2 mg/kg, IVIG, and nadroparin | 15        | 0                    |
| Yozgat, 2020      | Case report | 1 (0)                    | 3                           | NA            | NA                | NA                | IVIG and aspirin   | NA        | NA                   |
| First author, year | Study design | No. of patients (% males) | Age (years), median (range) | Ethnicity (n) | Comorbidities (n) | Oxygen support (n) | Treatment | Length of stay (days) | Death (n) |
|--------------------|--------------|----------------------------|-----------------------------|---------------|------------------|-------------------|------------|---------------------|-----------|
| Regev, 2020        | Case report  | 1 (100)                    | 16 NA                       | NA            | Diffuse brain hemosiderosis | Mechanical ventilation | IVIG, methylprednisolone, and aspirin | NA | 0 |
| Hutchison, 2020    | Case report  | 1 (100)                    | 14 NA                       | NA            | NA                | HFNC               | Vasopressors, IVIG, steroids, anticoagulants, and anankira | NA | 0 |
| Rodriguez-Gonzalez, 2020 | Case report | 1 (100)                    | 0.5 NA                      | NA            | Short bowel syndrome | Mechanical ventilation | Milrinone 0.5 mcg/kg/min, norepinephrine 0.2 mcg/kg/min, meropenem, vancomycin, and fluconazole | 21 | NA |
| Niño-Taravilla, 2020 | Case report | 1 (100)                    | 8 NA                        | None          | None              | Invasive mechanical ventilation (1) | Tocilizumab, methylprednisolone, and enoxaparin | 17 | 0 |
| Bahrami, 2020      | Case report  | 1 (0)                      | 5 NA                        | NA            | NA                | None               | IVIG (2 g/kg), high-dose acetylsalicylic acid, epinephrine, meropenem, vancomycin, and ciprofloxacin, and low-dose aspirin | NA | 0 |
| Carraro, 2020      | Case report  | 1 (0)                      | 5 Brazilian                 | None          | None              | None               | IVIG and aspirin | NA | 0 |
| Buonsenso, 2020    | Case report  | 1 (0)                      | 11 NA                       | NA            | NA                | NA                | NA | NA |
| Richardson, 2021   | Case report  | 1 (0)                      | 5 months                    | NA            | NA                | HFNC               | IVIG 2 g/kg, methylprednisolone 10 mg/kg, anakinra 4 mg/kg, infliximab 5 mg/kg, aspirin 5 mg/kg, and warfarin | 38 | 0 |

AKI=acute kidney injury; ASA=acetylsalicylic acid; BiPAP=bilevel positive airway pressure; ECMO=extracorporeal membrane oxygenation; HCQ=hydroxychloroquine; HFNC=high-flow nasal cannula; IL=interleukin; IV=intravenous; IVIG=intravenous immunoglobulin; IQR=interquartile range; LMWH=Low-molecular-weight heparin; NA=not available; NAFLD=non-alcoholic fatty liver disease; PDE3=phosphodiesterase enzyme 3; PPV=positive pressure ventilation; SD=standard deviation; SVIA=self-ventilating in air.
Table 2. Demographic and clinical characteristics, supporting examination, and treatment in PIMS-TS patients

| Variables                                      | n (%) | Reference range |
|------------------------------------------------|-------|-----------------|
| Age (years), mean (SD) (n = 698)               | 9.2 (4.1) | -               |
| Male gender (n = 698)                          | 405 (58.0) | -               |
| Ethnicity (n = 404)                            | -      | -               |
| African American/Afro-Caribbean/African        | 135 (33.4) | -               |
| White/European/Caucasian                       | 71 (17.6)  | -               |
| Hispanic/Latino                                | 53 (13.1)  | -               |
| Asian/Indian/Middle Eastern                    | 81 (20.0)  | -               |
| Others                                         | 64 (15.8)  | -               |
| Days of fever before admission, mean (SD) (n = 146) | 6.27 (2.7) | -               |
| Temperature upon admission (°C), mean (SD) (n = 51) | 39 (2) | -               |
| Systolic blood pressure (mmHg), mean (SD) (n = 42) | 81 (14)  | -               |
| Diastolic blood pressure (mmHg), mean (SD) (n = 36) | 46 (12) | -               |
| Signs and symptoms* (n = 698)                  | -      | -               |
| Fever                                          | 563 (80.6) | -               |
| Dyspnea                                        | 7 (1.0)   | -               |
| Tachyplea                                      | 30 (4.3)  | -               |
| Cough                                          | 85 (12.2) | -               |
| Oxygen desaturation                            | 13 (1.9)  | -               |
| Hypotension                                    | 59 (8.5)  | -               |
| Shock                                          | 251 (36.0) | -               |
| SARS-CoV-2 test* (n = 654)                     | -      | -               |
| IgM positive                                   | 2 (0.3)   | -               |
| IgG positive                                   | 181 (27.7) | -               |
| IgA positive                                   | 2 (0.3)   | -               |
| IgM and IgG positive                           | 11 (1.6)  | -               |
| IgG and IgA positive                           | 41 (6.3)  | -               |
| IgM, IgG, and IgA positive                     | 13 (1.9)  | -               |
| Negative                                       | 122 (18.7) | -               |
| Polymerase chain reaction test positive        | 244 (37.3) | -               |
| Not specified*                                 | 185 (28.3) | -               |
| Comorbidities* (n = 319)                       | -      | -               |
| Respiratory                                    | 34 (10.7) | -               |
| Neurologic                                     | 11 (3.4)  | -               |
| Endocrine                                      | 2 (0.6)   | -               |
| Gastrointestinal                               | 9 (2.8)   | -               |
| Cardiovascular                                 | 6 (1.8)   | -               |
| Nephrology                                     | 4 (1.2)   | -               |
| Hemato-oncology                                | 7 (2.1)   | -               |

Table 2. (continued)

| Variables                                      | n (%) | Reference range |
|------------------------------------------------|-------|-----------------|
| Nutritional issues                             | 62 (19.4)  | -               |
| Immunology/allergic                            | 8 (2.5)   | -               |
| Prematurity                                    | 3 (0.9)   | -               |
| Others                                         | 23 (7.2)  | -               |
| Length of stay (days), mean (SD) (n = 328)     | 9.8 (11.3) | -               |
| Outcome (alive) (n = 529)                      | 509 (96.2) | -               |
| Treatments received* (n = 621)                 | -      | -               |
| Intravenous immunoglobulin                     | 469 (75.5) | -               |
| Vasopressor                                    | 119 (19.2) | -               |
| Antibiotics                                    | 213 (34.3) | -               |
| Anticoagulants                                 | 206 (33.2) | -               |
| Diuretic                                       | 22 (3.5)  | -               |
| Nasal cannula for oxygen delivery              | 60 (9.7)   | -               |
| Non-invasive ventilation                       | 88 (14.2) | -               |
| Mechanical ventilation                         | 167 (26.9) | -               |
| Antiarrhythmics                                | 1 (0.2)   | -               |
| Remdesivir                                     | 17 (2.7)  | -               |
| Hydroxychloroquine                             | 11 (1.8)  | -               |
| Corticosteroids                                | 303 (48.8) | -               |
| Aspirin                                        | 166 (26.7) | -               |
| Convalescent plasma                            | 11 (1.8)  | -               |
| Anakinra                                       | 47 (7.6)  | -               |
| Tocilizumab                                    | 47 (7.6)  | -               |
| Hematologic                                    | -      | -               |
| Hemoglobin (g/dl) (n = 204), mean (SD)          | 9.6 (2.4)  | 11.5–14.5       |
| White blood cell count (10^3/µl) (n = 187), mean (SD) | 13.9 (6.2)  | 4–12           |
| Lymphocyte (%) (n = 87), mean (SD)              | 13 (13)   | 25–33           |
| Neutrophil (%) (n = 67), mean (SD)              | 74 (19)   | 57–67           |
| Platelets (10^3/µl) (n = 250), mean (SD)        | 165.7 (94.3) | 150–400       |

Table continued on next page
Table 2. (continued)

| Variables                                      | n (%) | Reference range |
|------------------------------------------------|-------|-----------------|
| Procalcitonin (µg/ml) (n = 80), mean (SD)       | 42 (78)| ≤0.15           |
| Lactate dehydrogenase (U/l) (n = 120), mean (SD)| 663.1 (280.9)| 150–500         |
| Creatine kinase (U/l) (n = 42), mean (SD)       | 145 (221)| 5–130           |
| Liver and kidney functions                     |       |                 |
| Creatinine (mg/dl) (n = 233), mean (SD)         | 13.15 (25.25)| 0.3–0.7         |
| Alanine transaminase (U/l), mean (SD)           | 103 (217)| 5–45            |
| Aspartate aminotransferase (U/l) (n = 83), mean (SD)| 95 (161)| 15–50           |
| Blood urea nitrogen (mg/dl) (n = 9), mean (SD)  | 55 (35)| 5–18            |
| Coagulation                                     |       |                 |
| D-dimer (mg/l) (n = 158), mean (SD)             | 2,923.59 (3,170)| <0.4           |
| Fibrinogen (mg/dl) (n = 214), mean (SD)         | 434.26 (293.77)| 220–440         |
| Erythrocyte sedimentation rate (mm/h) (n = 71), mean (SD)| 69 (29.0)| 0–20           |
| Cardiac                                         |       |                 |
| Troponin I (ng/l) (n = 27), mean (SD)           | 1,442 (5,693)| <300           |
| Troponin T (ng/l) (n = 94), mean (SD)           | 98 (182)| <100            |
| High sensitivity troponin I (ng/l) (n = 1), value| 29    | <100            |
| High sensitivity troponin T (ng/l) (n = 2), mean (SD)| 129.75 (43.25)| <14            |
| Unspecific troponin (ng/l) (n = 60), mean (SD)  | 1,425 (4,260)| <10             |
| BNP (pg/ml) (n = 41), mean (SD)                 | 3,224 (5,038)| 0–100           |
| NT-proBNP (pg/ml) (n = 13), mean (SD)           | 12,323 (12,150)| 0–450          |
| Echocardiography findings (n = 490)             |       |                 |
| Mitral regurgitation                            | 31 (6.3)|                 |
| Tricuspid regurgitation                         | 34 (6.9)|                 |
| Pericardial effusion + pericarditis             | 56 (11.4)|                |
| Myocarditis                                     | 29 (5.9)|                 |
| RV dysfunction                                  | 5 (1.0)|                 |
| Biventricular systolic dysfunction              | 3 (0.6)|                 |
| Coronary echogenicity                           | 18 (3.7)|                |

Table 2. (continued)

| Variables                                      | n (%) | Reference range |
|------------------------------------------------|-------|-----------------|
| Coronary artery dilatation                    | 27 (5.5)|                 |
| Coronary artery aneurysm                      | 26 (5.3)|                 |
| Aortic regurgitation                           | 4 (0.8)|                 |
| Pulmonary regurgitation                        | 2 (0.4)|                 |
| Coronary artery dilatation or aneurysm         | 18 (3.7)|                |
| Ectatic coronary artery                       | 15 (3.1)|                |
| Myocardial dysfunction                        | 5 (1.0)|                 |
| Cardiomegaly                                   | 10 (2.0)|                |
| Dilated left ventricle                         | 3 (0.6)|                 |
| Diastolic dysfunction                          | 5 (1.0)|                 |
| Left ventricle dysfunction                     | 199 (40.6)|              |
| LVEF (n = 281)                                 |       | ≥55%            |
|                                             | 82 (29.2)| 199 (70.8)     |
| LCA Z-score (n = 12)                           |       | <55%            |
|                                             | 8 (67)  | 0 (0)           |
|                                             | 0–2.5  | 4 (33)          |
| LAD Z-score (n = 6)                            |       | ≥2.5            |
|                                             | 4 (67)  | 2 (33)          |
| RCA Z-score (n = 18)                           |       | ≥2.5            |
|                                             | 8 (44)  | 9 (50)          |

BNP=brain natriuretic peptide; Ig=immunoglobulin; LAD=left anterior descending artery; LCA=left coronary artery; LVEF=left ventricular ejection fraction; NT-proBNP=N-terminal-pro hormone BNP; PIMS-TS=pediatric inflammatory multisystem syndrome temporally associated with COVID-19; RCA=right coronary artery; RV=right ventricle; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2; SD=standard deviation. *Each patient may have more than one test done/symptoms/comorbidities/treatment; †presented as serologies positive without further specifications.

(12%) were the most common abnormalities found in ECG (results not shown). Table 2 shows the echocardiographic findings on PIMS-TS patients, with left ventricle dysfunction (40.6%) being the most common abnormality, followed by pericardial effusion together with pericarditis (11.4%) and tricuspid regurgitation (6.9%). Echocardiographic findings showed that abnormalities were resolved in 88 days and ectatic coronary arteries in only 3 days.
(results are not shown in the table). Most patients presented with left ventricular ejection fraction (LVEF) of <55% (70.8%), left coronary Z-score of <2 (67%), left anterior descending artery Z-score of <2 (67%), and right coronary artery Z-score of ≥2.5 (50%).

**DISCUSSION**

We found that PIMS-TS is most prevalent among older children, and other studies have found a similar mean age of 7 to 10 years.²⁷,²⁸ Although they share similar clinical features, Kawasaki disease (KD) primarily affects children under 5 years old, with a median age of 2 years.²²,²⁹–³¹ Compared with KD, patients with PIMS-TS are more likely to present with gastrointestinal symptoms, such as abdominal symptoms, diarrhea, vomiting, and multiorgan involvement.³²

Shock and hypotension are the two most common signs of cardiovascular system as ventricular dysfunction is frequently encountered in PIMS-TS patients.³³ Previous studies found cardiovascular symptoms in 71% of patients.³⁷ Most myocardial involvement is usually moderate to severe, which is higher than in KD.³⁴

This review also reported inflammatory markers, particularly CRP as the most notable abnormalities in laboratory measurements. This reflects the hyperinflammatory nature of PIMS-TS,³⁵ as shown in other studies.³⁶,³⁷,³⁸ D-dimer and cardiac markers, such as troponin and brain natriuretic peptide, were also found to be elevated across all studies, confirming that myocardial involvement is indeed a hallmark feature of this disease.³⁶,³⁷,³⁸

Since PIMS-TS frequently involves the heart,³⁹ it is imperative to evaluate the patient's cardiac anatomy and function using echocardiography, cardiac CT, magnetic resonance imaging, and electrocardiography. In this systematic review, most patients had some cardiac involvements with a wide range of echocardiographic manifestations of PIMS-TS. The most common echocardiography abnormalities were reduced left ventricular (LV) function, pericardial effusion with pericarditis, myocarditis, and valvular abnormalities, which are similar to other systematic reviews.³⁶,³⁸,³⁹ Patients with impaired left ventricle function, specifically impaired LV global longitudinal strain and LV apical four-chamber peak longitudinal strain at clinical presentation, are at higher risk for developing adverse acute clinical course. Subclinical left myocardial dysfunction may persist for weeks after recovery in these patients. Thus, LV strain may be used to identify the higher-risk patients.⁴⁰ Coronary artery abnormalities were also found in a significant number of patients in this review, with coronary artery dilatation and aneurysms as the most common abnormalities, which also supported by other reviews.³⁶ Interestingly, most CT scans showed no abnormalities, with only a minority of patients manifesting cardiomegaly and pericardial effusion. Therefore, CT scans must be reconsidered to detect cardiovascular manifestation in children because it increases radiation exposure risk without generating significant findings. ST-segment and T wave abnormalities (32% and 12%, respectively) were most commonly reported in ECG, although most patients displayed normal ECG.

Cardiac abnormalities due to PIMS-TS, as shown in this review, represent a significant medical challenge that warrants more attention. This cardiac involvement may become a long-term health issue, as shown in a previous study that only 28.3% of patients had improved LVEF after hospital discharge.³⁹ Reduced LVEF may manifest as left-sided heart failure, which may cause fatigue, edema, and fluid retention, leading to a significant impairment on quality of life.⁴¹ Treatments should aim to minimize the long-term impact of PIMS-TS.

There are limitations to this systematic review. Since COVID-19 is still considered an emerging new disease, and the term PIMS-TS is relatively new, the knowledge of COVID-19 and PIMS-TS is constantly evolving and changing rapidly. To date, PIMS-TS has only been described from mid-2020. This review also has minimal cardiovascular clinical findings due to limited data. However, more than half of the patients had one or more cardiac abnormalities on echocardiography, emphasizing that most PIMS-TS patients survived the critical phase, although the long-term complications were not observed. Thus, further research is needed as the delayed complications should not be underestimated. In addition, we could not analyze the clinical and echocardiographic progression of the patients. Many cardiac abnormalities in PIMS-TS patients were lacking proper evaluation and follow-up. Many patients with PIMS-TS were not evaluated with echocardiography or only evaluated once at admission, which leads to difficulty in evaluating the progress of cardiac abnormalities that have developed. Due to the wide variety of data, we suggest future
studies to standardize the echocardiographic finding reports associated with PIMS-TS and assess the disease progression.

In conclusion, numerous organ or system dysfunctions may complicate the clinical course of pediatric patients with COVID-19. This review primarily focused on the possible development of various cardiac abnormalities, which were assessed by laboratory tests and imaging, with echocardiography as the leading modality in detecting and evaluating these patients. We should be more vigilant with cardiac abnormalities in COVID-19 pediatric patients and should not underestimate their consequences in pediatric patients. Thus, the importance of addressing cardiac abnormalities that may occur in PIMS-TS can not be understated.

**Conflict of Interest**
The authors affirm no conflict of interest in this study.

**Acknowledgment**
None.

**Funding Sources**
None.

**REFERENCES**

1. World Health Organization. WHO coronavirus (COVID-19) dashboard [Internet]. World Health Organization; 2021 [cited 2021 Jul 25]. Available from: https://covid19.who.int/.

2. Pudijadi AH, Putri ND, Sjakti HA, Yaniurso PB, Gunardi H, Roeslani RD, et al. Pediatric COVID-19: report from Indonesian Pediatric Society Data Registry. Front Pediatr. 2021;9:716898.

3. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. 2021;106:429–39.

4. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39(5):355–68.

5. Bhopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021;5(5):312–3.

6. Fernández-Sarmiento J, De Souza D, Jabornsly R, Gonzalez GA, Arias López MDP, Palacio G. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee. BMJ Paediatr Open. 2021;5(1):e000894.

7. Centers for Disease Control and Prevention. Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [Internet]. Centers for Disease Control and Prevention; 2021 [cited 2021 Aug 3]. Available from: https://www.cdc.gov/mis/cp/index.html.

8. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporarily related to COVID-19 [Internet]. World Health Organization; 2020 [cited 2021 Jul 29]. Available from: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-

9. Royal Collage of Paediatrics and Child Health. Paediatric multisystem inflammatory syndrome temporarily associated with COVID-19 (PIMS) - guidance for clinicians [Internet]. Royal Collage of Paediatrics and Child Health; 2020 [cited 2021 Jul 29]. Available from: https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance.

10. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-associated multisystem inflammatory syndrome in children — United States, March–July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074–80.

11. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325(11):1075–87.

12. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334–46.

13. Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–5.

14. Rodriguez-González M, Castellano-Martinez A, Cascales-Poyatos HM, Perez-Reveriego AA. Cardiovascular impact of COVID-19 with a focus on children: a systematic review. World J Clin Cases. 2020;8(21):5280–83.

15. Ramcharan T, Nolan O, Lal CY, Prabhu N, Krishnamurthy R, Richter AG, et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol. 2020;41(7):1391–401.

16. Prieto LM, Toral B, Llorente A, Coca D, Blázquez-Gamero D. Cardiovascular magnetic resonance imaging in children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 and heart dysfunction. Clin Microbiol Infect. 2020;26(4):e168–50.

17. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation. 2020;142(5):429–36.

18. Acevedo L, Piñeres-Olave BE, Niño-Serna LF, Vega LM, Gomez IJA, Chacón S, et al. Mortality and clinical characteristics of multisystem inflammatory syndrome temporally associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study). BMJ Pediatr. 2021;21(1):316.

19. Page MJ, McKenzie JE, Bossuyt PM, Bouttron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:721.

20. Joanna Briggs Institute. The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews: checklists for case reports [Internet]. Joanna Briggs Institute; 2019 [cited 2021 Jul 18]. Available from: https://jbi.global/sites/default/files/2019-05/JBI_Critical_Apraisal-Checklist_for_Case_Reports2017_0.pdf.

21. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. The Ottawa Hospital Research Institute; 2014. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

23. Kliegman RM, Carne J St, Blum NJ, Shah SS, Tasker RC, Wilson KM, et al. Nelson textbook of pediatrics. 21st ed. Philadelphia: Elsevier; 2020.

24. Pagana DK, Pagana TJ, Pagana TN. Mosby’s diagnostic and laboratory test reference. 12th ed. Botkin C, Bowlder NC, Burd
Santiago de Chile during the SARS-CoV-2 pandemic. Int J Infect Dis. 2020;100:75–81.

58. Darren A, Osman M, Masilamani K, Habib Ali S, Kanthimathinathan HK, Khemkaran R, et al. Vitamin D status of children with paediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS-TS). Br J Nutr. 2021;134(3):297–304.

59. Ng KF, Kotthoff T, Bandi S, Bird PW, Goyal K, Zoha M, et al. COVID-19 multisystem inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection. J Med Virol. 2020;92(11):2880–6.

60. Paolino J, Williams DA. Peripheral blood smears of children with multisystem inflammatory syndrome demonstrate prominence of early myeloid forms with morphologic evidence of toxic change. Pediatr Blood Cancer. 2021;68(3):e28551.

61. Harwood B, Partridge R, Minford J, Almond S. Paediatric abdominal pain in the time of COVID-19: a new diagnostic dilemma. J Surg Case Reports. 2020;2020(9):rjaa3337.

62. Lishman J, Kohler C, de Vos C, van der Zalm MM, Itana J, Redfern A, et al. Acute appendicitis in multisystem inflammatory syndrome in children with COVID-19. Pediatr Infect Dis J. 2020;39(12):1427–33.

63. Dalian C, Romano F, Siebert J, Politi S, Lacroix L, Sahyoun C. Septic shock presentation in adolescents with COVID-19. Lancet Child Adolesc Health. 2020;4(7):261–3.

64. Wolfer A, Mannarino S, Giacomet V, Camporesi A, Zuccotti G. Acute myocardial injury: a novel clinical pattern in children with COVID-19. Lancet Child Adolesc Health. 2020;4(8):826–7.

65. Rigo T, Mathur K, Purswani M. Systemic inflammation with cardiac involvement in pediatric patients with evidence of COVID-19 in a community hospital in the Bronx, New York. J Pediatr Infect Dis Soc. 2020;9(4):2502–3.

66. Shahbaznejad L, Navaeifar MR, Abbaskhanian A, Hosseinzadeh F, Rahimzadeh G, Rezai MS. Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran. BMC Pediatr. 2020;20(1):513.

67. Nathan N, Prevost B, Sileo C, Richard N, Berdah L, Thouvenin J-P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with COVID-19. J Pediatr. 2020;224:141–5.

68. Wehl C, Franke J, Frühwirth M, Edlinger M, Rauchenzauner M. Successful treatment of pediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) with split doses of immunoglobulin G and estimation of PIMS-TS incidence in a county district in southern Germany. Healthcare (Basel). 2021;9(4):481.

69. Mehta R, Ghosh S, Nandy J, Das S, Chattopadhyay A. Atypical presentation of complete heart block in children with pediatric inflammatory multisystem syndrome: a case series of two patients. Ann Pediatr Cardiol. 2021;14(3):408–11.

70. Mukund, Sharma M, Mehta A, Kumar A, Bhat V. Pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 - an emerging problem of PICU: a case series. J Pediatr Crit Care. 2020;7(5):271–5.

71. Capone CA, Subramony A, Sweberg T, Schneider J, Shah S, Rubin L, et al. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection. J Pediatr. 2020;222:141–5.

72. Whittaker E, Bamford A, Kenny J, Kafourou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324(3):259–69.

73. Blumfeld E, Levin TL. COVID-19 in pediatric patients: a case series from the Bronx, NY. Pediatr Radiol. 2020;50(10):1369–74.

74. Waltuch T, Gill P, Zins LE, Whitney R, Tokarski J, Tsung JW, et al. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department. Am J Emerg Med. 2020;38(10):2246.e3–6.

75. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. J Pediatric Infect Dis Soc. 2020;9(3):393–8.

76. Patel ST, Wright H. Lessons of the month: a misunderstood teenager with paediatric inflammatory multisystem syndrome - temporally associated with SARS-CoV-2 admitted under adult medicine. Clin Med (Lond). 2021;21(1):296–9.

77. Gupta VK, Shenoy S, Palek K, Tudu MN. Severe Paediatric multisystem inflammatory syndrome (PIMS) in a 23 months old baby post COVID-19 effectively managed with IVIG and pulse steroid: case report. Res Sq. 2020:1–4.

78. Rauf A, Vijayan A, John ST, Krishnan R, Latheef A. Multisystem inflammatory syndrome in children with features of atypical Kawasaki disease during COVID-19 pandemic. Indian J Pediatr. 2020;87(9):745–7.

79. Gupta A, Gill A, Sharma M, Garg M. Multisystem inflammatory syndrome in children: a case report series. J Trop Pediatr. 2021;67(7):fmaa60.

80. Balsubaramanian S, Nagendran TM, Ramachandran B, Ramanan A V. Hyper-inflammatory syndrome in a child in COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. Indian Pediatr. 2020;57(7):681–3.

81. Schneider DT, Pütz-Dolderer J, Bierang J. Pediatric multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Dtsch Arztebl Int. 2020;117(25):431.

82. Orlanski-Meyer E, Yogev D, Auerbach A, Megged O, Glikman D, Hashkes PJ, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus-2 in an 8-week old infant. J Pediatric Infect Dis Soc. 2020(9):781–4.

83. Mash M, Moll S, Raza N. Paediatric case of prolonged COVID-19 manifesting as PMIS-TS and atypical Kawasaki. BMJ Case Rep. 2020;13(9):e237914.

84. Meredith J, Khedim CA, Henderson P, Wilson DC, Russell RK. Infliximab attenuates paediatric inflammatory multisystem syndrome in children with COVID-19 (PIMS-TS). Preprints 2020, 202006018.

85. Ghatasheh G, Al Dhanhani H, Goyal A, Noureddin MB, Al Awaad D, Peerwani Z. COVID-19-related giant coronary aneurysms in an infant with multisystem inflammatory disorder in children: the first case report from the United Arab Emirates and the Arab region. Case Rep Infect Dis. 2021;2021:20218724.

86. Dasgupta K, Finch SE. A case of pediatric multisystem inflammatory syndrome temporally associated with COVID-19 in South Dakota. S D Med. 2020;73(6):246–51.

87. Klocerko A, Parackova Z, Dissou J, Malcova H, Pavlicek P, Vymazal T, et al. Case report: systemic inflammatory response and fast recovery in a pediatric patient with COVID-19. Front Immunol. 2020;11:1665.

88. Yozgat CY, Uzuner S, Bursal Duramaz B, Yozgat Y, Erenberk U, Işcan A, et al. Dermatological manifestations of pediatric multisystem inflammatory syndrome associated with COVID-19 in a 3-year-old girl. Dermatol Ther. 2020;33(4):e13770.

89. Regev T, Antemi M, Eydan D, Shachor-Meyouhas Y, Illivitzki A, Aviel Y, et al. Pediatric inflammatory multisystem syndrome with central nervous system involvement and hypocomplementemia following SARS-COV-2 infection. Pediatr Infect Dis J. 2020;39(8):e206–7.

90. Hutchison L, Plichta AM, Dossou J, Malcova H, Pavlicek P, Vymazal T, et al. Case report: systemic inflammatory response and fast recovery in a pediatric patient with COVID-19. Front Immunol. 2020;11:1665.

91. Niño-Taravilla C, Espinosa-Vielma YP, Otalo-Arca H, Poli-Harlowe C, Tapia LI, Ortiz-Fritz P. Pediatric inflammatory
multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab. Pediatr Rep. 2020;12(1):142–8.
93. Bahrami A, Vafapour M, Moazzami B, Rezaei N. Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: first case from Iran. J Paediatr Child Health. 2021;57(6):922–5.
94. Carraro M, Rocha Rodrigues B, Rodrigues Jr. V. Case report: multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 with coronary involvement. Arch Clin Biomed Res. 2020;4(6):760–5.
95. Buosenso D, Di Sante G, Sali M; CURE COVID-19 Study Group. Cytokine profile in an adolescent with pediatric multisystem inflammatory syndrome temporally related to COVID-19. Pediatr Infect Dis J. 2020;39(8):e213–5.
96. Richardson KL, Jain A, Evans J, Uzun O. Giant coronary artery aneurysm as a feature of coronavirus-related inflammatory syndrome. BMJ Case Rep. 2021;14(7):e238740.